Adaptimmune Therapeutics Operating Income 2015-2021 | ADAP

Adaptimmune Therapeutics operating income from 2015 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Adaptimmune Therapeutics Annual Operating Income
(Millions of US $)
2020 $-133
2019 $-140
2018 $-82
2017 $-81
2016 $-73
2015 $-23
2014 $-14
2013 $-14
Adaptimmune Therapeutics Quarterly Operating Income
(Millions of US $)
2021-06-30 $-39
2021-03-31 $-38
2020-12-31 $-38
2020-09-30 $-36
2020-06-30 $-30
2020-03-31 $-30
2019-12-31 $-30
2019-09-30 $-40
2019-06-30 $-36
2019-03-31 $-34
2018-12-31 $-32
2018-09-30 $7
2018-06-30 $-29
2018-03-31 $-29
2017-12-31 $-30
2017-09-30 $-5
2017-06-30 $-24
2017-03-31 $-22
2016-12-31 $-15
2016-09-30 $-19
2016-06-30 $-23
2016-03-31 $-17
2015-12-31
2015-09-30 $-8
2015-06-30 $-11
2015-03-31 $-6
2014-12-31
2014-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.899B $0.004B
Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29